Express Scripts (ESRX) Reports In-Line Q4 EPS; Raises Mid-Point of FY16 EPS

Express Scripts (NASDAQ: ESRX) reported Q4 EPS of $1.56, in-line with the analyst estimate of $1.56. Revenue for the quarter came in at $26.18 billion versus the consensus estimate of $26.58 billion.

GUIDANCE:

Express Scripts sees FY2016 EPS of $6.10-$6.28, versus prior guidance of $6.08-$6.28 and the consensus of $6.15.

"Our business model of alignment, developed 30 years ago, has never been more relevant than it is today," said George Paz, Chairman and CEO. "Our job is to continue to take advantage of the opportunities and uniquely help clients withstand the constant challenges in the healthcare marketplace by taking bold actions to effectively balance pharmacy cost and care. Our focused alignment continues to control client costs, improve patient care and drive long term value to our shareholders."

"Building upon our strongest retention year ever, an outstanding 1/1/16 performance and the industry's deepest set of cost-saving solutions, Express Scripts has momentum that maintains our confidence in our 2016 guidance and justifies our excitement about our future," said Tim Wentworth, President. "Financially and operationally, we are well positioned to drive growth and deliver value to clients and shareholders."

For earnings history and earnings-related data on Express Scripts (ESRX) click here.

You May Also Be Interested In

• Morgan Stanley CEO: investment banking momentum is building - Conference Call
• Barrick Gold (GOLD) reported preliminary Q1 production of 940 thousand ounces of gold
• Main Street Capital (MAIN) Reports Prelim Q1 Results